S tudy assess I n G the morbidity-mortality be N efits of the I f inhibitor ivabradine in patients with coronar Y artery disease without heart failure.

Slides:



Advertisements
Similar presentations
Programme: 145 sessions & social events
Advertisements

patients, 51 countries, 1139 centers Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of.
UNIVERSITY OF JYVÄSKYLÄ INTERNATIONAL COOPERATION.
The management of outpatients with stable coronary artery disease in clinical practice.
Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med August 31. DOI: /NEJMoa
Knowledge Management LXV International Council Meeting Qawra, Malta 16 th - 23 rd of March 2014.
Kenneth W. Mahaffey Daniel M. Wojdyla Stefan K. James Hugo A. Katus Steen Husted Gabriel Steg Christopher P. Cannon Richard C. Becker Claes Held Nardev.
S ystolic H eart failure treatment with the If inhibitor ivabradine T rial Michel Komajda on behalf of the Investigators.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Area Definition III KAM,Bratislava. The European Law Students’ Association Albania ˙ Austria ˙ Azerbaijan ˙ Belgium ˙ Bosnia and Herzegovina ˙ Bulgaria.
Design and baseline characteristics. Trial hypothesis Fox K et al. Am Heart J. 2013;166(4): SIGNIFY is assessing whether heart rate reduction.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Objective, design and baseline Swedberg.
ELSA Law Schools ICM Cluj-Napoca, 21st April 2015.
Results of the 1 st Phase of the International GLORIA-AF Registry Program: Regional Treatment Differences Before the Era of Novel Anticoagulants MV Huisman,
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):
A step further in the management of stable coronary patients with ivabradine.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
Capitalist. Main Points In a capitalist or free-market country, people can own their own businesses and property. People can also buy services for private.
Make it Smart&Creative ICM Cluj-Napoca, 21st April 2015.
Doing Business in Europe Bay Area CITD Seminar Series Tuesday, September 21st, 2004 Kemarra Inc. - Key Marketing Resources & Associates San Francisco USA.
Institutional Visit LXV International Council Meeting Qawra, Malta 16 th - 23 rd of March 2014.
S ystolic H eart failure treatment with the If inhibitor ivabradine T rial Michel Komajda and Karl Swedberg on behalf of the Investigators.
ELSA as the Franchise? LXV International Council Meeting Qawra, Malta 16 th - 23 rd of March 2014.
Map - Region 3 Europe.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
< Return to Largest Religious CommunitiesLargest Religious Communities The Largest Atheist / Agnostic Populations Top 50 Countries With Highest Proportion.
Europe. Albania AL Austria Belarus Belgium.
Computer Class – Summer 20092/21/2016 3:45 AM European Countries Albania Andorra Austria Belarus Belgium Bosnia and Herzegovina Bulgaria Croatia Czech.
2016 Global Manufacturing Competitiveness Index. 2Deloitte and US Council on Competitiveness I 2016 Global Manufacturing Competitiveness IndexCopyright.
Geography Review On Map 1, please identify: -Spain -France -England -Russia -Ottoman empire -Persia -China -Mughal India -Songhai Empire.
Country EPS-12 Total (with ICPS) Hungary7979 Germany5559 Romania3841 Ukraine2527 United Kingdom1930 Finland1842 France1616 Italy1616 Poland1313 Switzerland1314.
The European Law Students’ Association Albania ˙ Austria ˙ Azerbaijan ˙ Belgium ˙ Bosnia and Herzegovina ˙ Bulgaria ˙ Croatia ˙ Cyprus ˙ Czech Republic.
SS-1 Candesartan Support Slides. SS-2 Baseline Beta-Blocker Charm Added β-blocker Of patients on β-blockers Mean daily dose of β-blocker CandesartanPlacebo.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Figure 1. PARTICIPATING STEM CELL DONOR REGISTRIES Number of registries Year ©BMDW.
Bed Linen Markets in the World to 2017 Bharat Book Bureau.
Global Aluminium Foil Market to Market Size, Growth, and Forecasts in Nearly 60 Countries Published on : Jul 2014.
Global Powered Lawn Mower Market to Market Size, Growth, and Forecasts in Nearly 70 Countries “This comprehensive publication enables readers the.
Global Printing Ink Market to Market Size, Growth, and Forecasts in Over 70 Countries “This comprehensive publication enables readers the critical.
Global Aluminium Pipe and Tube Market to 2018 (Market Size, Growth, and Forecasts in Nearly 60 Countries) Published Date: Jul-2014 Reports and Intelligence.
Pinger and IEPM-BW activity at FNAL By Frank Nagy FTP/CCF Computing Division Fermilab.
IEC System of Conformity Assessment Schemes for Electrotechnical Equipment and Components.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
IEC System of Conformity Assessment Schemes for Electrotechnical Equipment and Components.
Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Enoxaparin Versus Unfractionated.
Table 1. Number and rate of reported confirmed syphilis cases per population by country and year, EU/EEA, 2010–2014 ASR: age-standardised rate,
Table 1. Number and rate of Legionnaires’ disease cases per population by country and year, EU/EEA, 2010–2014 ASR: age-standardised rate, C: case-based.
France Ireland Norway Sweden Finland Estonia Latvia Spain Portugal Belgium Netherlands Germany Switzerland Italy Czech Rep Slovakia Austria Poland Ukraine.
Table 1. Reported confirmed hepatitis A cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N =
DISTRIBUTION AUTOMATIC - GENERATION
The 1680 Family’s Reach.
Electrification Products
Locations where Black Panther was released in the theaters in 2018.
Citi Virtual Card Accounts – Continued Global Expansion
Sourcing. Costs. HARDWARE + SERVICE
The European Parliament – voice of the people
The European Parliament – voice of the people
Намалување на загадувањето на воздухот со електромобилност
European survey respondents by region.
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Adriatic Persian Gulf Map Test #1 Answers.
Table 1. Reported confirmed leptospirosis cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N.
European Union Membership
“Integrating Microbial Knowledge into Human Life”
Adriatic Persian Gulf Map Test #1 Answers.
European representation of respiratory critical care HERMES participants. European representation of respiratory critical care HERMES participants. Countries.
Infographics on Electromobility. APRIL 2019.
Presenter Disclosure Information
Electrification business
Presentation transcript:

S tudy assess I n G the morbidity-mortality be N efits of the I f inhibitor ivabradine in patients with coronar Y artery disease without heart failure Conflict of interest Kim Fox receives honoraria, fees, travel expenses from Servier

Study organisation Executive Committee K Fox (Chair, UK), R Ferrari (Co-chair, Italy), I Ford (UK), PG Steg (France), J-C Tardif (Canada), M Tendera (Poland) Endpoint Validation Committee K Thygesen (Chair, Denmark), M Frenneaux (UK), G Jondeau (France), A Mosterd (The Netherlands) Data Monitoring Committee J Camm (Chair, UK), G Murray (UK), H Dargie (UK), J Kjekshus (Norway), AP Maggioni (Italy)

Study organisation Steering committee Argentina: Argentina: R Iglesias Armenia: Armenia: PA Zelveian Australia: Australia: B Freedman Austria: Austria: K Huber Belgium: Belgium: JL Vanoverschelde Brazil: Brazil: LA Machado Cesar Bulgaria: Bulgaria: N Gotcheva Canada: Canada: P L’Allier China: China: DY Hu Croatia: Croatia: M Bergovec Czech Republic: Czech Republic: J Hradec Denmark: Denmark: P Clemmensen, and P Hildebrandt Estonia: Estonia: J Eha Finland: Finland: M Laine France: France: N Danchin FYROM: FYROM: S Kedev Germany: Germany: T Münzel Georgia: Georgia: V Chumburidze Greece: Greece: P Vardas Hong-Kong: Hong-Kong: CP Lau Hungary: Hungary: J Borbola India: India: R Kasliwal Ireland: Ireland: P Crean Italy: Italy: R Ferrari Kazakhstan: Kazakhstan: TZ Seisembekov Korea: Korea: KB Seung Latvia: Latvia: A Erglis Lithuania: Lithuania: A Laucevicius Malaysia: Malaysia: R Ali Mexico: Mexico: E Alexanderson The Netherlands: The Netherlands: WH van Gilst and JW Jukema Norway: D Atar Philippines: R Sy Poland: A Rynkiewicz Portugal: R Seabra Gomes Romania: Romania: C Macarie Russia: Russia: VY Mareev and YA Karpov Serbia: Serbia: MC Ostojic Singapore: Singapore: TH Koh Slovakia: Slovakia: J Murin Slovenia: Slovenia: P Rakovec South Africa: South Africa: P Sareli Spain: Spain: C Macaya de Miguel Sweden: Sweden: M Dellborg Switzerland: Switzerland: T Lüscher Taiwan: Taiwan: CE Chiang Thailand: Thailand: P Sritara Turkey: Turkey: O Ergene United Kingdom: United Kingdom: A Hall Ukraine: Ukraine: A Parkhomenko Uruguay: F Kuster Vietnam: Vietnam: NV Pham

Patients with heart rate ≥70 bpm (n= 5392) Placebo Ivabradine HR (95% CI), 0.64 (0.49–0.84) P=0.001 Years Effect of ivabradine on hospitalization for fatal/nonfatal MI in patients with stable CAD and LVSD Overall placebo population (n=5438) Fox K et al. Lancet. 2008;372: HR (95% CI), 1.46 (1.11–1.91) P= Years Heart rate <70 bpm Heart rate ≥70 bpm Fox K et al. Lancet. 2008;372: Event rate (%)

Study outcomes Events: 2.8% PY placebo, N= Median follow-up: 27.8 months 51 countries centres Population  55 years, stable CAD With at least one other CV risk factor (including angina CCS class  II) Without clinical heart failure (LVEF >40%) HR  70 bpm Primary composite end point: cardiovascular death or nonfatal myocardial infarction Primary analysis: ivabradine versus placebo on primary end point Prespecified analysis: in patients with angina CCS class ≥II on primary end point Ivabradine 7.5 mg bid Matching placebo, bid Run-in 14 to 30 days M1M2 Every 6 months D0M3 Ivabradine 5, 7.5, or 10 mg bid according to heart rate (target bpm) and tolerability M6 Study design Fox K et al. Am Heart J. 2013;166:

Patients and follow-up patients randomized Ivabradine (n=9550) Placebo (n=9552) 9552 analyzed 9550 analyzed 235 had incomplete follow-up 231 withdrew consent 3 lost to follow-up 1 medical reason 200 had incomplete follow-up 199 withdrew consent 1 lost to follow-up 6037 with angina 3513 with no angina 6012 with angina 3540 with no angina

Baseline characteristics Ivabradine n=9550 Placebo n=9552 Age, years 6565 Male, % 7372 Resting heart rate, bpm 7777 LV ejection fraction, % 5656 Previous MI, % 7373 Previous coronary revasc, % 6868 Dyslipidemia, % 7272 Diabetes mellitus, % 4343 Peripheral artery disease, % 2121 Current smoker, % 2424 Hypertension, % 8786

Baseline cardiovascular medications Ivabradine n=9550 Placebo n=9552 Antiplatelet or anticoagulants, % 9898 Statins, % 9292 ACE inhibitors or ARB, % 8281 Beta-blockers, % 8383 Dihydropyridine CCB, % 2727 Diltiazem or verapamil, % 54 Organic nitrates, % 4139

Mean heart rate reduction Time (months) Heart rate (bpm) Placebo Ivabradine Mean reduction = 9.7 bpm 95% CI [-10.0 ; -9.5]

Ivabradine n=654 (3.03% PY) Placebo n=611 (2.82% PY) [ HR = 1.08 [95% CI ] P=0.20 Primary composite end point Time from randomization (months) Ivabradine Numbers at risk Patients with event (%) Placebo Ivabradine

Cardiovascular death Time from randomization (months) Patients with event (%) Ivabradine Placebo Numbers at risk Ivabradine n=329 (1.49% PY) Placebo n=301 (1.36% PY) [ HR = 1.10 [95% CI ] P=0.25 Placebo Ivabradine

Nonfatal myocardial infarction Patients with event (%) Time from randomization (months) Ivabradine n=351 (1.63% PY) Placebo n=339 (1.56% PY) [ HR = 1.04 [95% CI ] P=0.60 Numbers at risk Ivabradine Placebo Ivabradine

Incidence of selected adverse events (n=19 083) Ivabradine (n=9539) % (n) Placebo (n=9544) % (n) Symptomatic bradycardia Symptomatic bradycardia 7.9 (757) 1.2 (110) Asymptomatic bradycardia Asymptomatic bradycardia 11.0 (1047) 1.3 (126) Atrial fibrillation 5.3 (508) 3.8 (362) Phosphenes Phosphenes 5.4 (512) 0.5 (52)

Incidence of selected adverse events (n=19 083) Ivabradine (n=9539) % (n) Placebo (n=9544) % (n) Ventricular tachycardia Ventricular tachycardia 0.6 (54) 0.4 (41) Ventricular fibrillation Ventricular fibrillation 0.3 (27) 0.3 (26) Torsades de pointes Torsades de pointes 0 (1) 0 (3)

Primary composite end point (angina population: CCS class ≥ II, n=12 049) Ivabradine n=459 (3.37% PY) Placebo n=390 (2.86% PY) [ HR = 1.18 [95% CI ] P= Time from randomization (months) Placebo Ivabradine Patients with event (%) Ivabradine Placebo Numbers at risk

Components of primary composite end point (angina population: CCS class ≥II, n=12 049) Time from randomization (months) Patients with event (%) Ivabradine Placebo Numbers at risk Time from randomization (months) Patients with event (%) Placebo Ivabradine Ivabradine n=235 (1.72% PY) Placebo n=200 (1.47% PY) [ HR = 1.18 [95% CI ] P=0.09 Ivabradine n=245 (1.76% PY) Placebo n=210 (1.51% PY) [ HR = 1.16 [95% CI ] P=0.11 Cardiovascular death Nonfatal myocardial infarction

Effect of ivabradine on symptoms (angina population: CCS class≥ II, n=12 049) Patients (%) P<0.01 Elective revascularization Ivabradine 2.8% Placebo 3.5% HR 0.82

Conclusion  Lowering heart rate with ivabradine in CAD patients without clinical heart failure does not reduce the risk of CV death or nonfatal MI  In the subgroup of patients with angina (CCS class ≥II), there appeared to be an increase in CV death or nonfatal MI  In the same subgroup there appeared to be improvement in symptoms and need for elective coronary revascularization

Acknowledgements patients from 51 countries patients from 51 countries 1139 centers 1139 centers More than 5400 investigators More than 5400 investigators Study supported by Study supported by

Fox K et al. N Engl J Med. Published online 31 August Now available online from NEJM